Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?

Authors

  • Helano de Paula Gonçalves Souza Instituto do Câncer do Ceará (ICC). Fortaleza (CE), Brasil. https://orcid.org/0000-0001-9641-0765
  • Francisco Pimentel Cavalcante Instituto do Câncer do Ceará (ICC). Fortaleza (CE), Brasil.
  • José Carlos Lucena de Aguiar Ferreira Universidade Estadual do Ceará (UECE). Fortaleza (CE), Brasil.
  • Rafael Valente Batista Universidade Estadual do Ceará (UECE). Fortaleza (CE), Brasil.
  • Marcos Venício Alves Lima Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Rio de Janeiro (RJ), Brasil. https://orcid.org/0000-0002-4944-5022

DOI:

https://doi.org/10.32635/2176-9745.RBC.2015v61n1.759

Keywords:

Sentinel Lymph Node Biopsy, Carcinoma, Ductal, Breast, Carcinoma, Intraductal, Noninfiltrating

Abstract

Introduction: Carcinoma in situ accounts for approximately 15% of breast cancers. By definition, it does not exceed the basal membrane, which would imply zero theoretical risk for lymph node metastasis. However, according to the literature, 1-13% of sentinel lymph node biopsies (SNB) in patients with carcinoma ductal in situ (DCIS) are positive. Objective: To determine the prevalence of sentinel lymph node metastasis in patients with DCIS treated surgically at a referral hospital in Northeastern Brazil. Method: Cross-sectional and descriptive study using secondary data obtained from the medical records of patients with breast cancer that underwent surgery at the Cancer Institute of Ceará (ICC) between 2002 and 2012. The data were analyzed with the software Epi Info 7.0. Results: The study population included 746 patients with primary breast tumors, being 106 (14%) of them diagnosed with DCIS on the initial histological examination. Fifty-four patients (51%) underwent mastectomy and 52 (49%) conservative surgery. SNB was performed in 88 (83%) of 106 cases of DCIS, but only one case (1.1%) was positive. During follow-up of the 106 DCIS patients, 2 had local recurrence and 1 had loco regional recurrence. Conclusion: SNB in patients with DCIS alone revealed a low prevalence of lymph node metastasis, matching most studies on the topic. Despite the low morbidity of SNB, the additional financial cost and its negligible impact on therapeutic decision suggest the procedure is not indispensable in this patient population.

Downloads

Download data is not yet available.

Published

2015-03-31

How to Cite

1.
Souza H de PG, Cavalcante FP, Ferreira JCL de A, Batista RV, Lima MVA. Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?. Rev. Bras. Cancerol. [Internet]. 2015 Mar. 31 [cited 2024 Dec. 23];61(1):37-42. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/759

Issue

Section

ORIGINAL ARTICLE